in the treated population. Furthermore, no published Canadian guidelines are available to suggest appropriate strategies for the management of vte in patients with solid tumours. We therefore aimed to develop a clear evidence-based guideline on this topic, specifically to provide recommendations for physicians, nurses, and other front-line staff about the prophylaxis and treatment of vte in patients with cancer, specifically those with solid tumours, both in the inpatient and the ambulatory settings. The questions addressed were these:
• What is the standard of care for patients with solid tumours with established vte? • Among patients with solid tumours, who should receive prophylactic antithrombotic therapy for vte? • What are the most common complications associated with antithrombotic therapy use, and how should special clinical scenarios be managed?
METHODOLOGY

Guideline Development
The review process for this guideline was developed based on an overview from the U.K. National Institute for Health and Clinical Excellence of clinical guideline development for stakeholders, the public, and the U.K. National Health Service 15 ; on Cummings and Rivara's methodology for reviewing manuscripts published in the Archives of Pediatrics and Adolescent Medicine 16 ; and on the agree collaboration instrument 17 . With that methodologic foundation, the guideline recommendations were drafted by a medical oncologist from the Tom Baker Cancer Centre (Calgary, AB), a hematologist from the University of Alberta (Edmonton, AB), and a cancer research methodologist from CancerControl Alberta. The guideline was reviewed by an expert panel of medical oncologists, hematologic oncologists, a surgical oncologist, a registered nurse, and a physiotherapist, representing urban and rural centres in Alberta. The evidence base for the guideline was informed by a systematic review of the literature.
Literature Search Strategy
The PubMed database of the U.S. National Library of Medicine was searched for relevant articles published between 2002 and 2013. In addition, the American Society of Clinical Oncology (asco) was searched for meeting abstracts published between 2010 and 2013, and the U.S. National Guideline Clearinghouse was searched for guidelines published between 2007 and 2013. Search terms included "neoplasm" or "cancer" and "venous thromboembolism" or "thrombosis" and "thrombosis prophylaxis" or "vte prophylaxis." Results were limited to randomized controlled trials and phase iii and iv clinical trials published between 2002 and March 2013, as well as meta-analyses published between 2008 and March 2013. Trials that did not report outcomes related to the prophylaxis or treatment of vte were excluded. Because of a lack of translation services, articles in other than the English language were also excluded from the review of the evidence.
RESULTS AND DISCUSSION
Results of the Literature Review
The literature review included seven clinical practice guidelines, six meta-analyses, and twenty-eight randomized controlled trials. Several relevant retrospective case series were also included in the discussion, but were not considered strong evidence when developing the recommendations. Table ii presents a summary of the evidence for the use of prophylactic anticoagulation. 
Discussion
Treatment of Established VTE in Ambulatory Patients with Solid Tumours
Venous thromboembolism typically presents as dvt or pe. The signs and symptoms of dvt include pain, edema or swelling in the limbs or upper body, persistent cramping, and erythema. The signs and symptoms of pe include, but are not limited to, chest pain, shortness of breath, hypoxia, tachycardia, and tachypnea 42 . It is important to note that none of the signs or symptoms of dvt and pe are sensitive or specific for vte, and that the index of suspicion should be high when patients with these symptoms also have a substantial risk for vte (such as the presence of cancer). In addition to a clinical evaluation, imaging is required to diagnose dvt (that is, ultrasonography) and pe (that is, pe-protocol computed tomography imaging, ventilation-perfusion scan) 43 . Initial therapy for established vte in cancer patients should be a low molecular weight heparin (lmwh) [42] [43] [44] [45] .
For maintained anticoagulation, lmwh has been shown to be more effective than warfarin therapy in cancer patients on active cancer treatment. The clot trial, which included cancer patients with acute symptomatic proximal dvt, pe, or both (n = 672), compared lmwh (specifically, dalteparin) with daily warfarin as maintenance therapy. All patients were initially treated for 6 months with either dalteparin (200 IU/kg daily subcutaneously for 1 month and 150 IU/kg daily for 5 months) or warfarin [international normalized ratio (inr) 2-3] for 6 months. Recurrent vte occurred in 8% (27 of 336) of the dalteparin group and 16% (53 of 336) of the warfarin group (hazard ratio: 0.48; p = 0.002). Major bleeding and any bleeding did not differ between the groups (6% vs. 4% and 14% vs. 19% respectively) 46 . The lite trial compared tinzaparin with warfarin in patients with cancer and acute symptomatic proximal dvt (n = 200). After 12 months of follow-up, recurrent vte occurred in 7% (7 of 100) of the tinzaparin group and in 16% (16 of 100) of the vitamin K antagonist group [relative risk (rr): 0.44; p = 0.044]. Bleeding did not differ between the groups (27% vs. 24%) 47 .
VTE Prophylaxis in Ambulatory Patients with Solid Tumours
Prophylaxis is an important consideration in the care of patients with cancer, especially those with active risk factors (erythropoiesis stimulating-agent use, exogenous estrogen use, antiangiogenic therapy use, and recent surgery) 5, [10] [11] [12] [13] . A model developed by Khorana et al. 5, 8 could be useful in assessing vte risk based on specific patient factors ( Table iii) . The asco clinical practice guideline suggests that the model is intriguing, but does not endorse its use as a formal recommendation 48 .
Several meta-analyses on the role of vte prophylaxis have been performed and include patients with central venous catheters 36 , patients undergoing neurosurgical procedures 33 , patients with lung cancer receiving chemotherapy 35 , and patients with cancer undergoing surgery 29 . Data from twelve randomized controlled trials involving patients with a central venous catheter suggest that the risk of symptomatic and asymptomatic dvt might potentially be reduced with the use of prophylactic lmwh (compared with no treatment); however, statistical significance was not reached (rr: 0.54; 95% ci: 0.28 to 1.05; and rr: 0.81; 95% ci: 0.64 to 1.02 respectively). Moreover, no significant reduction in the risk of mortality was observed between patients treated with prophylactic lmwh and those who received no treatment (rr: 0.85; 95% ci: 0.53 to 1.37) 36 .
Among patients undergoing neurosurgery, the use of prophylactic lmwh (compared with no treatment) was shown, in an analysis of eighteen randomized controlled trials, to reduce the risk of dvt by 40% (rr: 0.60; 95% ci: 0.44 to 0.81) 33 . Data from patients with lung cancer receiving chemotherapy who also received prophylactic lmwh (specifically, nadroparin or certoparin) were compared with data from patients on placebo in the topic-2 trial. The relative risk of thromboembolic events was reduced by 46% with lmwh (rr: 0.54; 95% ci: 0.31 to 0.95) 33 . Symptomatic vte was also reduced by 42% with the use of prophylactic lmwh, but nonsignificantly (rr: 0.58; 95% ci: 0.28 to 1.06) 45 . Table ii provides a brief summary of the evidence.
The type of prophylactic anticoagulant agent used in patients with cancer might be of less importance. Data from fourteen randomized controlled trials that compared prophylactic lmwh and unfractionated heparin (ufh) in patients with cancer 50 . Despite the observed benefit of anticoagulants, the risk of major bleeding in patients without vte was increased for anticoagulant users compared with control subjects (rr: 2.60; 95% ci: 1.94 to 3.45; p = 0.000) 51 . Current guidelines do not recommend the use of anticoagulants to improve survival in patients with cancer without vte, but they do support the participation of patients with cancer in clinical trials designed to evaluate anticoagulant therapy as an adjunct to standard anticancer therapies 48 .
3.2.3
Contraindications and Special Considerations with Antithrombotic Therapy Use of antithrombotic therapy is contraindicated in patients with life-threatening bleeding or severe thrombocytopenia. The asco guidelines do not recommend anticoagulant prophylaxis or therapy in patients with a platelet count below 50,000/μL 48 . Acute vte carries a significant risk of early recurrence, extension, or embolization in the absence of anticoagulation even in thrombocytopenic patients. Thus, anticoagulant options for individuals with a platelet count below 50,000/μL should be reviewed with a specialist, and close patient monitoring is required. That approach is supported by recommendations from the International Society on Thrombosis and Haemostasis 52 . Decisions on treatment and dose should be made case by case with the utmost caution. Otherwise, anticoagulation therapy is relatively safe, and most patients should be eligible.
The most common side effect of anticoagulant therapy is bleeding. According to a meta-analysis of data from the protecht and topic-2 studies, the rate of major bleeding with lmwh is only slightly greater than that with placebo (2.5% vs. 1.7%) 53 . The risk of bleeding from antithrombotic therapy must be weighed against the possible therapeutic benefits; overall, however, anticoagulant therapy appears to be safe in patients without active bleeding. Major bleeding associated with lmwh is low (<1%) 24, 34, 41 .
The use of lmwh should be cautious in patients with renal impairment (creatinine clearance ≤ 30 mL/ min) 48 . Accumulation of lmwh because of reduced excretion can occur in patients with impaired renal function; accumulation results in an increased risk of bleeding. However, data suggest that not all lmwh drugs carry the same risk of accumulation; in fact, higher molecular weight lmwh drugs might be less dependent on kidney clearance.
Of the available lmwhs, tinzaparin has the highest average molecular weight at 6500 Da, compared with enoxaparin at 4400 Da 54 . Among patients with moderate renal impairment (creatinine clearance 30-50 mL/min) who received therapeutic enoxaparin (1 mg/kg every 12 hours or 1.5 mg/kg once daily) for 6 months, clinically relevant bleeding occurred in 22% (13 of 59); such bleeding occurred in 6% of patients (6 of 105) with normal renal function (odds ratio: 3.9; 95% ci: 0.97 to 15.6; p = 0.055) 55 . Therapeutic and prophylactic doses of tinzaparin have been shown to be a safer alternative to other lmwh options in patients with renal insufficiency (serum creatinine ≥300 μmol/L and creatinine clearance > 20 mL/min, or creatinine clearance 20-30 mL/ min) [56] [57] [58] . The American College of Chest Physicians (accp) guidelines reference data showing that tinzaparin clearance is not correlated with creatinine clearance, even at a rate as low as 20 mL/min [58] [59] [60] .
Data for dalteparin use in severe renal dysfunction are limited. The direct study included critically ill patients (n = 138) with a creatinine clearance less than 30 mL/min given dalteparin (5000 IU daily) in the prophylactic setting. No patients (0%; 95% ci: 0% to 3.0%) showed bioaccumulation (that is, anti-factor xa > 0.40 IU/mL), and the median trough anti-factor xa concentration was undetectable (<0.10 IU/mL) 61 . Similar findings have been reported elsewhere 62 .
Indications for the use of an inferior vena cava (ivc) filter include recent proximal dvt plus an absolute contraindication to anticoagulation 56, 63, 64 . Failure of anticoagulation, poor compliance with anticoagulation, and falls are not indications for an ivc filter. Changing or intensifying anticoagulation, appropriate patient counselling, increased patient monitoring, and interventions to reduce the bleeding risk can be explored in such situations. Inferior vena cava filters are associated with high morbidity and can increase hypercoagulability; therefore, if placement is required, the filter should be removed as soon as possible (that is, once lmwh can be started). No available data support the addition of an ivc filter to pharmacologic anticoagulation therapy 52, 65 . Conversely, patients with an ivc filter who can receive pharmacologic anticoagulation therapy should continue treatment as long as they are deemed at high risk of recurrent vte regardless of the presence or absence of a filter. Contraindications to anticoagulation include a high risk for bleeding, current bleeding, and severe thrombocytopenia 63, 64 .
Because of the bleeding risk associated with surgery, caution must be used in patients already taking anticoagulation therapy. According to the accp guidelines, patients scheduled for surgery should stop lmwh 24 hours before surgery or ufh 4-6 hours before surgery. In patients undergoing a high-bleeding-risk surgery, therapeutic doses of lmwh and ufh should not be re-started until the high-risk period for bleeding is over 66 . Prophylaxis for dvt (low-dose heparin or ufh) can be initiated earlier, often on postoperative day 1 if there is no active bleeding. In patients undergoing a low-bleeding-risk surgery (dermatologic, ophthalmologic, dental), anticoagulation therapy can usually be continued through the procedure. If anticoagulation is discontinued, therapeutic anticoagulation with lmwh should be resumed within 24 hours after the procedure if hemostasis is adequate 56 . Postoperative vte prophylaxis is recommended based on evidence in a Cochrane Collaboration review of data from four clinical trials in patients undergoing major abdominal or pelvic surgery; the incidence of overall vte (dvt and pe) and symptomatic vte was lower in the extended lmwh group (14.3% vs. 6.1%, p < 0.0005, and 1.7% vs. 0.2%, p = 0.02, respectively) 67 . Evidence about the effect of lmwh on bleeding risk after a biopsy is limited. A retrospective study in children (n = 190) undergoing ultrasound-guided liver biopsy showed that, for 3 major and 28 minor bleeding incidents, lmwh was a risk factor 68 . Patients scheduled to receive a biopsy can be considered low risk and be treated at the discretion of the treating physician.
Heparin-induced thrombocytopenia (hit) is thrombocytopenia that occurs as the result of heparin use. The accp guidelines recommend that hit be investigated if the individual's platelet count falls by 50% or more or if a thrombotic event occurs (or both) from day 5 to day 14 (inclusive) after initiation of heparin 59 . Strongly suspected (or confirmed) hit, whether complicated by thrombosis or not, should be treated with an alternative non-heparin anticoagulant such as danaparoid, lepirudin, argatroban, fondaparinux (off-label), or bivalirudin [69] [70] [71] [72] [73] [74] [75] [76] . After the platelet count has substantially recovered (usually to at least 150×10 9 /L), warfarin can be started, with the non-heparin anticoagulation used as bridging therapy until the inr is therapeutic 59 . The British Committee for Standards in Haematology has issued recommendations that are concordant with those of the accp 66,77 . A history of confirmed or suspected hit is a contraindication to the use of lmwh and ufh 78-80 .
CONCLUSIONS
Although the use of antithrombotic agents is contraindicated in patients with active life-threatening bleeding, antithrombotic therapy is otherwise relatively safe, and most patients are eligible for therapy at the discretion of the treating physician. Figure 1 presents a clinical algorithm for the use of antithrombotic therapy in patients with cancer.
Summary of Recommendations on Treatment of Established VTE in Patients with Solid Tumours
Proximal lower-extremity dvt and pe are indications for antithrombotic therapy. Other vte manifestations should be considered for antithrombotic therapy based on symptoms and risk factors. There is no consensus on duration of therapy. Trials using lmwh in cancer patients studied 3-6 months of treatment, followed by standard of care at the discretion of the treating physician. Options can include cessation of therapy, continuation of lmwh, or a switch to an oral agent. Patients with metastatic disease will continue to be at high risk for vte and could potentially be treated indefinitely at the discretion of the treating physician 46 . Patients being treated for vte should be aware of their condition and planned treatment; be informed of the signs and symptoms of dvt and pe, and of the side effects of anticoagulation therapy; and be instructed to inform other health care providers that they are using antithrombotic therapy. Education should be provided by health care professionals with oncology experience. In both ambulatory patients and inpatients for whom antithrombotic therapy is not contraindicated, lmwh (that is, dalteparin, tinzaparin, or enoxaparin) is the treatment of choice because of lesser recurrence rates on treatment; however, if the patient has non-dialysis-dependent severe kidney failure, tinzaparin should be considered the agent of choice. Dalteparin is dosed subcutaneously at 200 U/kg daily for 1 month, and then 150 U/kg daily. No consensus has been reached on the dose of enoxaparin for cancer-associated thrombosis; however, for some physicians, 1 mg twice daily or 1.5 mg/kg once daily are accepted approaches 46, 81, 82 . Tinzaparin is dosed subcutaneously at 175 U/kg daily 47 . Unfractionated heparin can be used at the discretion of the treating physician under select circumstances only (for example, when rapid clearance of anticoagulants is desired). Typically, ufh is given intravenously at 80 U/kg, then 18 U/kg/h or according to electronic medical record algorithms or validated online dosing calculators based on partial thromboplastin time.
New oral anticoagulant agents (apixaban, dabigatran, rivaroxaban) have not yet been proved to be efficacious or safe in oncology patients. Although less favoured, oral warfarin (adjusted to inr 2-3) can be used, especially in situations in which lmwh is contraindicated or the patient refuses lmwh. Warfarin has been shown to be inferior to tinzaparin and dalteparin in randomized clinical trials in cancer patients. To bridge warfarin until the inr reaches the therapeutic range, lmwh or ufh should be used.
According to the accp guidelines 66 , patients scheduled for surgery should stop lmwh 24 hours before the procedure or ufh 4-6 hours before the procedure. Therapeutic doses of lmwh and ufh should not be restarted until the high-risk period for bleeding has resolved (typically at least 3 days after surgery). In hemodynamically stable patients, lmwh or ufh for dvt prophylaxis can be initiated earlier (often on postoperative day 1).
Summary of Recommendations on VTE Prophylaxis in Patients with Solid Tumours
High-risk cancer patients (that is, patients with a Khorana risk factor score of 3 or greater 5 , 48 . Patients being considered for prophylaxis with antithrombotic therapy should be informed of their risk of vte and of the signs and symptoms of dvt and pe, as well as the side effects of anticoagulation therapy (that is, risk of bleeding). Nonpharmacologic prophylaxis (for example, compression stockings) and early mobilization should be considered for patients unable to receive pharmacologic agents (typically those who are actively bleeding).
Summary of Recommendations on Contraindications and Special Considerations with Antithrombotic Therapy
Bleeding is the most common complication of anticoagulation therapy. Major bleeding while on anticoagulation requires immediate cessation of all antithrombotic therapy and presentation to an emergency department where an appropriate treatment algorithm can be initiated. Minor bleeding can be assessed in clinic and might require anticoagulant cessation at the discretion of the physician. Follow-up visits should assess for bleeding complications and ensure that self-injections are administered properly. Visits should occur initially between 1 week and 1 month after the start of antithrombotic therapy, and then at 6 months. A baseline complete blood count is required to ensure that anticoagulation is safe; severe thrombocytopenia might require dose adjustment or non-antithrombotic alternatives. The first follow-up complete blood count should be checked within 5-10 days of starting either lmwh or ufh to assess for hit-a rare but life-threatening complication of heparin-based therapy. The complete blood count should then be regularly checked-at monthly intervals at a minimum. Patients and their caretakers should be informed about vte and its treatment. The benefits of treatment should be weighed against the risks. Patients should also be trained in self-injection with the assistance of the clinic nurse. Items that should be reviewed include vte risk and options to lower the risk; symptoms of a blood clot, particularly pe; what to do if symptoms are suspected; the purpose of anticoagulation medication; restrictions when taking anticoagulation medication; risks of using or taking anticoagulation medication; post-thrombotic syndrome; and blood clot prevention.
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